Tulane University awarded $9.2 million NIH contract for innovative oral vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID), within the National Institutes of Health (NIH), has awarded a contract for up to $9.2 million over the next five years to Tulane University to collaborate with Biotech company Q-Vant Biosciences Inc. to develop a promising new platform for oral vaccines that could be used to prevent a variety of infectious diseases. Read the full story here.